A detailed history of Headlands Technologies LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Headlands Technologies LLC holds 12,630 shares of CERE stock, worth $0. This represents 0.06% of its overall portfolio holdings.

Number of Shares
12,630
Previous 611 1967.1%
Holding current value
$0
Previous $25,000 1964.0%
% of portfolio
0.06%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$38.96 - $42.75 $468,260 - $513,812
12,019 Added 1967.1%
12,630 $516,000
Q1 2024

May 07, 2024

BUY
$40.88 - $43.27 $24,977 - $26,437
611 New
611 $25,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.